Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Heska Announces Executive Promotions to Further Growth Initiatives

Posted on: 30 Sep 16

LOVELAND, Colo., Sept. 29, 2016 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA)  (News; "Heska" or the "Company"), a provider of veterinary diagnostic and specialty products, today reported several key executive promotions as part of its ongoing growth initiatives. Mr. John McMahon is promoted to Chief Financial Officer. Mr. Jason Napolitano continues as Chief Operating Officer and adds the role of Chief Strategist. Mr. Steve Eyl is promoted to Executive Vice President, Global Sales and Marketing. All three executives will report to Mr. Kevin Wilson, Heska's Chief Executive Officer and President. Nancy Wisnewski, PhD, was named Executive Vice President, Diagnostic Operations & Product Development, reporting to Mr. Napolitano.

"For the past three years, Heska has grown revenues and profitability at a rapid pace, in a healthy manner, while capturing market share and establishing a broad base of customers to drive long-term recurring revenue," said Kevin Wilson. "Today, we are augmenting and reorganizing our leadership team to leverage this success and solidify Heska's position. As we take our next major growth steps in business development, product development, geographic expansion, and market share, we also continue to execute our plans for expanding talent and team excellence with today's promotions."

John McMahon, Chief Financial Officer. 
John McMahon, CPA is promoted to be the Company's Chief Financial Officer. Mr. McMahon, aged 51, was appointed Vice President, Financial Operations & Controller in October of 2015. Over the past year Mr. McMahon has worked well and closely with Mr. Napolitano, CFO, COO and the Audit Committee of the Company's board of directors.

Bonnie Trowbridge, Chairperson of the Company's Audit Committee, commented, "John has the demonstrated expertise, ethics, and leadership that reaffirms our initial confidence in his selection as a key member of Heska's team. We are excited to promote him to his new role as Heska's Chief Financial Officer."

Mr. Wilson, Heska's CEO and President added, "John has proven himself more than ready for the larger role I anticipated for him when we first began work together last year. I am excited to announce his promotion today."

Jason Napolitano, Chief Operating Officer, Chief Strategist. 
Jason Napolitano has been Heska's Chief Financial Officer and Executive Vice President since 2002. In preparation of today's announcement to strengthen and broaden Heska's executive team, Mr. Napolitano was made the Company's Chief Operating Officer in October of 2015. With today's promotion, Mr. Napolitano will continue in his role of Chief Operating Officer and will today also assume the role of Chief Strategist. From 1990 to 2001, Mr. Napolitano held various positions at Credit Suisse First Boston, an investment bank, including Vice President in health care investment banking and Director in mergers and acquisitions. He holds a B.S. degree from Yale University.

"Jason's deep and longstanding understanding of Heska's business, combined with his sharp intelligence and strong work ethic make him a cornerstone member of our team," said Kevin Wilson, the Company's CEO and President. "In his new role as Chief Strategist, I am excited to work closely with Jason to develop Heska's significant opportunities within the global veterinary healthcare space. Because Jason understands the fine details and the broad trends within Heska, the veterinary diagnostics market, and the health care mergers and acquisitions space, he is uniquely qualified to help Heska reach a much larger role within the veterinary healthcare industry."

Steve Eyl, Executive Vice President, Global Sales and Marketing. 
Steve Eyl is promoted to be the Company's Executive Vice President, Global Sales and Marketing. Mr. Eyl has been Heska's Executive Vice President, Commercial Operations since May 2013. Mr. Eyl was President of Sound Technologies, Inc. ("Sound") from 2000 to 2011, including after Sound's acquisition by VCA Antech, Inc. in 2004.

"I have known and trusted Steve since our days together at Sound beginning in 2000," added Mr. Wilson. "Steve joined Heska in May of 2013 with a clear goal: to make Heska's commercial teams excellent. By any measure it is clear that he has done a fantastic job. As we expand our efforts to international markets, expand our business development activities, and broaden our product offerings, I am confident that Steve's leadership, judgment and winning expectations will carry the day for Heska."

Nancy Wisnewski, PhD, Executive Vice President Diagnostic Operations & Product Development. 
Dr. Wisnewski is promoted to Executive Vice President Diagnostic Operations & Product Development.

Mr. Wilson added, "Nancy has done a fantastic job for Heska since 1993. As we continue to grow, it is important to frame key roles and responsibilities more precisely. Nancy's contributions to Heska's success are innumerable. With this promotion, I am pleased to highlight her critical role in making Heska the leader in operations and quality in the veterinary diagnostics space. As we expand further, continuing this excellence is key to our plans."

Dr. Wisnewski was appointed Executive Vice President, Product Development and Customer Support in April 2011. She served as Vice President, Product Development and Technical Customer Service from December 2006 to April 2011. From January 2006 to November 2006, Dr. Wisnewski was Vice President, Research and Development. Dr. Wisnewski holds a Ph.D. in Parasitology/Biochemistry from the University of Notre Dame and a B.S. in Biology from Lafayette College.

About Heska 
Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. For further information on Heska and its products, visit

Forward-Looking Statements 
This announcement contains forward-looking statements. These statements are based on current expectations and are subject to a number of risks and uncertainties. Factors that could affect the business and financial results of Heska generally include, but are not limited to, the following: uncertainties related to Heska's ability to measure and predict trends in the veterinary market; uncertainties related to Heska's ability to measure and predict the effectiveness of personnel and commercial relationships; uncertainties related to the future impact of recent business development activity; risks related to Heska's reliance on third-party suppliers, which is substantial; competition; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the three months ended June 30, 2016.

For more information:

Editor's Details

Mike Wood

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.